MARIA REIS: Open Payments
NPI 1124195680 · PLYMOUTH MEETING, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,515 in 79 payments from 10 companies in 2025. Trend: 2023 $1,498 · 2024 $864 · 2025 $1,515
Food & beverage: $1,515
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 24 | $355 |
| Neurocrine BioSciences, Inc. | 5 | $206 |
| Collegium Pharmaceutical, Inc. | 12 | $204 |
| Teva Pharmaceuticals USA, Inc. | 10 | $204 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $203 |
| Supernus Pharmaceuticals, Inc. | 11 | $202 |
| Alkermes, Inc. | 2 | $42 |
| E.R. Squibb & Sons, L.L.C. | 2 | $39 |
| Lundbeck LLC | 2 | $36 |
| Corium, LLC | 3 | $25 |
Products named: INGREZZA, Jornay PM, CAPLYTA, Qelbree, REXULTI, UZEDY, ABILIFY ASIMTUFII, ABILIFY MAINTENA.
Industry payments across PA — which companies pay providers there.
